Jonathan Wolleben
Stock Analyst at JMP Securities
(4.28)
# 363
Out of 4,944 analysts
213
Total ratings
50%
Success rate
15.6%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Market Outperform | $55 → $52 | $21.01 | +147.50% | 12 | Aug 13, 2025 | |
| ATXS Astria Therapeutics | Maintains: Market Outperform | $25 → $26 | $6.78 | +283.76% | 3 | Aug 13, 2025 | |
| QNCX Quince Therapeutics | Maintains: Market Outperform | $9 → $8 | $1.69 | +373.37% | 2 | Aug 12, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $90 → $86 | $29.38 | +192.72% | 15 | Aug 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $67 → $69 | $56.35 | +22.45% | 12 | Aug 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $79 → $81 | $65.00 | +24.62% | 11 | Aug 7, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $89 → $87 | $18.77 | +363.51% | 10 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Market Outperform | $130 → $135 | $96.55 | +39.82% | 4 | Aug 6, 2025 | |
| ALT Altimmune | Maintains: Market Outperform | $25 → $15 | $3.70 | +305.41% | 13 | Jul 10, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $19 → $27 | $12.87 | +109.79% | 4 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.03 | +294.09% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $9.85 | +113.20% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $3.16 | +374.68% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.06 | +169.12% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.44 | +1,049.43% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $443 | $370.93 | +19.43% | 12 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $12.68 | +199.68% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $12.35 | +53.85% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $8.38 | +114.80% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.86 | +214.69% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $44.59 | +12.13% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $88.30 | +1.93% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $124.44 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $704.24 | -31.13% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $9.34 | +242.61% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $3.83 | +552.74% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.51 | +1,460.98% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $31.81 | -24.55% | 1 | May 12, 2023 |
Pharvaris
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $21.01
Upside: +147.50%
Astria Therapeutics
Aug 13, 2025
Maintains: Market Outperform
Price Target: $25 → $26
Current: $6.78
Upside: +283.76%
Quince Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $1.69
Upside: +373.37%
Crinetics Pharmaceuticals
Aug 11, 2025
Maintains: Market Outperform
Price Target: $90 → $86
Current: $29.38
Upside: +192.72%
Protagonist Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $67 → $69
Current: $56.35
Upside: +22.45%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Market Outperform
Price Target: $79 → $81
Current: $65.00
Upside: +24.62%
Structure Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $18.77
Upside: +363.51%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Market Outperform
Price Target: $130 → $135
Current: $96.55
Upside: +39.82%
Altimmune
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $3.70
Upside: +305.41%
KalVista Pharmaceuticals
Jul 8, 2025
Maintains: Market Outperform
Price Target: $19 → $27
Current: $12.87
Upside: +109.79%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.03
Upside: +294.09%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $9.85
Upside: +113.20%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $3.16
Upside: +374.68%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $7.06
Upside: +169.12%
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.44
Upside: +1,049.43%
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $370.93
Upside: +19.43%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $12.68
Upside: +199.68%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $12.35
Upside: +53.85%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $8.38
Upside: +114.80%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.86
Upside: +214.69%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $44.59
Upside: +12.13%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $88.30
Upside: +1.93%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $124.44
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $704.24
Upside: -31.13%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $9.34
Upside: +242.61%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $3.83
Upside: +552.74%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.51
Upside: +1,460.98%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $31.81
Upside: -24.55%